HALI MILLER: Open Payments
NPI 1700330396 · BOGALUSA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$348 in 14 payments from 6 companies in 2025. Trend: 2023 $299 · 2024 $7,308 · 2025 $348
Food & beverage: $243Education: $104
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 7 | $200 |
| Neurocrine BioSciences, Inc. | 3 | $86 |
| Lundbeck LLC | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: INGREZZA, UZEDY, AUSTEDO XR, ABILIFY ASIMTUFII, CAPLYTA, COBENFY.
Industry payments across LA — which companies pay providers there.
